Piclozotan

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Piclozotan
Piclozotan.png
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H24ClN3O2
Molar mass409.909 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

See also[edit]

References[edit]

  1. ^ Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T.; Tatsuoka, T. (2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–1992. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.
  2. ^ Ferro, J.; Dávalos, A. (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823.
  3. ^ Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–115. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037.